View Cart  

Guidance: Single Trial May Be Enough for ABOM Drugs

Sponsors of treatments for acute bacterial otitis media (ABOM), an inflammation of the middle ear, may be able to use a single clinical trial to support an application under some circumstances, according to a final FDA guidance.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00